Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A one-way open-label study to compare the efficacy, safety, and pharmacokinetics of HPN-100 (glycerol phenylbutyrate) with sodium phenylbutyrate in patients with urea cycle disorders, as well as a long-term extension study

Next Previous
Search
Trial Profile

A one-way open-label study to compare the efficacy, safety, and pharmacokinetics of HPN-100 (glycerol phenylbutyrate) with sodium phenylbutyrate in patients with urea cycle disorders, as well as a long-term extension study

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glycerol phenylbutyrate (Primary) ; Sodium phenylbutyrate
  • Indications Inborn urea cycle disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors OrphanPacific

    • Most Recent Events

    • 27 Dec 2024 According to an Immedica media release, OrphanPacific, Inc has submitted an application to the Ministry of Health, Labour and Welfare in Japan for the approval of Ravicti (glycerol phenylbutyrate) for the treatment of Urea Cycle Disorders (UCD). The submission follows the approval of the orphan drug designation of Ravicti on December 25.
    • 21 Apr 2023 Status changed from planning to recruiting, according to an Immedica media release.
    • 21 Apr 2023 According to an Immedica media release, first patient has been enrolled in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top